Q-omics provides the consensus-scored SPO11 profile across patient tissues and cancer cell-line models. SPO11 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, SPO11 is differentially expressed in 4, with the highest sampling consensus in THCA. Additionally, SPO11 protein abundance shows 13,194 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight COAD, THCA, and LUAD as cancer lineages where SPO11 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SPO11 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SPO11 survival associations across molecular data types. SPO11 RNA expression shows survival associations in the most cancer types (14), followed by mutation status (6) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SPO11 RNA expression–survival associations across cancer types. High SPO11 expression shows unfavorable associations in COAD, KIRC and UVM, but favorable associations in STAD, HNSC and OV. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for SPO11 RNA expression.
This table summarizes SPO11 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4, while mass-spec protein shows differences in 4. The strongest signals are observed in THCA for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for SPO11. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SPO11 shows lower tumor expression in THCA and higher tumor expression in BRCA, LUAD and LUSC. The THCA box plot shows higher SPO11 RNA expression in normal versus tumor tissue (log2 FC = −0.084, t-test p < 0.001).
This table shows molecular features associated with SPO11 in patient tissues and cancer cell lines. In patient samples, SPO11 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, SPO11 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in OVARY and LARGE_INTESTINE.
